Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06407973 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
A Phase 4 study, sponsored by Sight Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT06407973 is a Phase 4 study that was terminated before completion, run by Sight Sciences. The registered enrollment target is 2 participants.
The verdict
NCT06407973, a Phase 4 study, was terminated before completion, sponsored by Sight Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
Interventions
- DEVICE OMNI Surgical System
- DRUG Latanoprost plus adjunctive glaucoma medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-01-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06407973
The ClinicalTrials.gov registry entry for NCT06407973 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sight Sciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OMNI Surgical System is the first listed.
NCT06407973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06407973 about?
NCT06407973 is a clinical study titled "A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma". A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
What is the current status of trial NCT06407973?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2024-08-21. Estimated completion is 2025-01-20.
What interventions are being tested in trial NCT06407973?
The interventions under investigation include: OMNI Surgical System (DEVICE), Latanoprost plus adjunctive glaucoma medication (DRUG).
Who is sponsoring clinical trial NCT06407973?
This trial is sponsored by Sight Sciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.